WALTHAM, Mass • 2024-01-03

GlobalData Names BostonGene Leading Innovator in AI-Driven Drug Repurposing

5 min to read

Recognition Highlights Dedication to Innovation and the Transformative Impact of AI-driven Solutions to Advance Drug Development

WALTHAM, Mass –January 3, 2024 – BostonGene, a leading provider of AI-driven, molecular and immune profiling solutions, today announced that it has been named a leading innovator in AI drug repurposing in a recent report published in Pharmaceutical Technology, part of the GlobalData network. The article, “Innovators in AI Drug Repurposing: Pioneering AI in the Pharmaceutical Industry,” showcases BostonGene at the forefront of innovation by leading in both geographical reach and application diversity. BostonGene’s groundbreaking contributions to the pharmaceutical industry, driven by artificial intelligence (AI)-based and advanced bioinformatics solutions, with the company holding more than 200 patents, solidified its leadership position in total patent count.

GlobalData analyzed over 260 companies, spanning technology vendors, established pharmaceutical companies and up-and-coming start-ups engaged in the development and application of drug repurposing AI to determine their leadership ranking.

AI-driven drug repurposing, a cutting-edge approach to drug discovery and development, leverages AI-powered machine learning algorithms to identify existing drugs that may have efficacy in diseases or disease subtypes different from the original intended patient population. This innovative approach may significantly reduce the time and cost of bringing new therapies to market. BostonGene’s AI-driven solutions have already been instrumental in accelerating drug discovery and development processes. The company’s proprietary platform utilizes the power of AI to analyze vast datasets, including genetic, clinical, and molecular information, to uncover novel uses for existing therapeutics. BostonGene’s mission is to improve patient outcomes by providing customized, cost-effective solutions with fast turnaround times, to get the right drugs to the right patients.

“We are honored to be recognized as innovators in AI drug repurposing,” said Andrew Feinberg, President and CEO at BostonGene. “With hundreds of patents in our portfolio, our team is committed to harnessing the potential of AI to transform drug discovery and to benefit patients worldwide. This recognition reflects our commitment to advancing research and bringing new hope to those in need.”

BostonGene’s contributions to AI-driven drug repurposing align with its broader mission of advancing precision medicine by tailoring treatments to individual patients. By leveraging AI and bioinformatics, BostonGene unlocks the full potential of existing drugs while reducing the risks and costs associated with traditional drug development.

Pharmaceutical Technology, part of the GlobalData network, is a renowned industry publication known for its insightful coverage of the latest developments and innovations in the pharmaceutical sector. With a strong commitment to delivering timely and relevant information, Pharmaceutical Technology plays a pivotal role in informing professionals and stakeholders about the cutting-edge advancements shaping the pharmaceutical industry.

About BostonGene Corporation

BostonGene is a company at the intersection of technology and biology, dedicated to advancing and personalizing cancer medicine. Founded in 2015, BostonGene has continually pushed the boundaries of innovation to improve cancer patient care and accelerate research and drug development through cutting-edge solutions. Leveraging our AI-powered multiomics platform, we digitize and comprehensively analyze the molecular profiles of cancer patients, including the immune system and tumor microenvironment. Our software solutions, indication-specific cancer library and advanced bioanalytics, enable us to discover multiparametric signatures, identify targets, match them to relevant indications for biopharma and recommend the most effective treatments for patients. For more information, visit www.BostonGene.com.

Erin Keleher O'Reilly

Senior Director

+1-617-283-2285

Erin.Oreilly@BostonGene.com